From All Angles brings together patients, caregivers, and healthcare experts to explore the latest advancements in cancer treatment. Each episode offers a comprehensive view of oncology care, integrating personal experiences with clinical insights to provide a holistic understanding of treatment practices.
Bispecifics in Multiple Myeloma: Patient Journey and Clinical Insights
July 30th 2025Binod Dhakal, MD, MS, and Karen Kehl discuss how bispecific antibody therapy with talquetamab has transformed the treatment journey for a multiple myeloma patient who achieved durable responses after 19-plus prior treatments, exploring the drug's mechanism targeting GPRC5D, clinical trial data showing 70% response rates, practical considerations including step-up dosing strategies and manageable adverse effects like taste changes and nail issues, and the patient's positive quality of life outcomes that have allowed her to continue living actively 16 years post diagnosis.
Managing CAR T Therapy in R/R MM: Patient and Expert Perspectives
July 29th 2025Leyla O. Shune, MD; Mindy Kupchin, RN; and Tina Kellogg discuss how chimeric antigen receptor (CAR) T-cell therapy has emerged as a superior second-line treatment for relapsed/refractory multiple myeloma (MM), sharing clinical insights on the CARTITUDE-4 trial results, patient experience with ciltacabtagene autoleucel, and the multidisciplinary care coordination required to successfully deliver this immunotherapy that offers patients deeper remissions, improved quality of life, and potentially prolonged survival compared with standard chemotherapy approaches.
Patient-Centered Care and Treatment Innovation in Renal Cell Carcinoma
December 16th 2024Panelists discuss how a multidisciplinary, patient-centered approach, including shared decision-making and the integration of immunotherapy and targeted therapies, is essential for optimizing the treatment and management of advanced renal cell carcinoma (RCC).
CAR T-Cell Therapy in Multiple Myeloma
December 3rd 2024Panelists discuss how chimeric antigen receptor (CAR) T-cell therapy is transforming the treatment of relapsed/refractory multiple myeloma, highlighting the decision-making process, patient preparation, management of adverse effects, and the importance of multidisciplinary collaboration to optimize outcomes and improve quality of life.
CAR-T Therapy for Second-Line Treatment in High-Risk Multiple Myeloma
November 27th 2024Panelists discuss how multiple myeloma patients and healthcare providers navigate the comprehensive CAR-T therapy journey, from initial diagnosis through treatment selection, therapy administration, and long-term follow-up care, while sharing clinical insights and personal experiences about treatment outcomes, side effect management, and quality of life improvements.
Managing Advanced HER2+ Breast Cancer: Expert and Patient Perspectives
October 31st 2024Panelists discuss how a multidisciplinary approach and shared decision-making are crucial in managing advanced HER2+ breast cancer, emphasizing the integration of expert insights with patient experiences for optimal treatment outcomes.
Exploring Advanced Renal Cell Carcinoma: Expert and Patient Perspectives
November 28th 2023Thomas Hutson, DO, PharmD, leads a discussion with his patient, Mr. Cesar Fuentes, and colleague Kacie Ellis, RN, focusing on the evolving treatment practices in advanced renal cell carcinoma and sharing patient and clinician perspectives.
The Bladder Cancer Patient Journey
June 23rd 2023Moderator Rohit Jain, MD, MPH leads a discussion with Anand Shah, PharmD, BCOP, Mr. Jeffery Ehas, and Mrs. Lauren Ehas, focusing on the evolving treatment practices in bladder cancer. Panelists assess the latest data, evaluate the impact on treatment decisions, and share patient and caregiver perspectives.